[ad_1] CNBC’s Jim Cramer said Tuesday that Elon Musk’s disclosure that he takes prescription ketamine for depression was courageous and “saved a lot of people from killing themselves.” “I defend him as much as possible because there are many people who would never be brave enough to admit they take this drug,” Cramer said on…
[ad_1] Vertiv Holdings : The data center equipment maker, whose shares have roughly quadrupled over the past year, issued guidance that didn’t live up to Wall Street’s lofty expectations. However, the stock is now trading well off its lows of the morning. “Data center still strong. Buy,” Jim Cramer said. Teladoc Health : Shares tumbled…
[ad_1] CNBC’s Jim Cramer called out General Electric as a winner in the industrial sector for the strides it’s making in nuclear power. GE’s Verona Nuclear Fuel business said Wednesday it received approval from the U.S. Nuclear Regulatory Commission to manufacture, ship, and analyze the performance of higher enrichment fuel. These “regulatory milestones” will help…
[ad_1] Clorox – The consumer products giant saw a huge earnings beat. It’s also rebounding from last year’s cyberattack. “Things are back online, and there’s tremendous demand for their product,” Jim said Friday’s Morning Meeting rapid fire. Tesla – The EV leader issued a recall for 2.2 million cars over a warning light issue. Remember,…
[ad_1] Traders work at the post where UnitedHealth Group is traded on the floor of the New York Stock Exchange. Brendan McDermid | Reuters UnitedHealth Group‘s (UNH) quality quarterly results Friday are a good sign for the broader health-care landscape, CNBC’s Jim Cramer said. The managed-care giant earned an adjusted $6.56 per share on revenues…
[ad_1] CNBC’s Jim Cramer on Wednesday praised the incoming CEO of Walgreens Boots Alliance, saying industry veteran Tim Wentworth is the right choice to lead the struggling pharmacy chain in its transition to offering more health-care services. “This guy is the real deal. I just salute him and think he can take you to a…
[ad_1] CNBC’s Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid. “The biggest pharmacy issue [is] how do we get pain removed, or at least nullified, without opiates? They have a plan — Vertex,” Cramer…
[ad_1] Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company’s macular degeneration treatment. If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free. CNBC’s Jim Cramer said on “Squawk on the Street” that Regeneron…
